5 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

2. Nkarta, Inc. (NASDAQ:NKTX)

Akkaraju and Dybbs’ Stake Value: $64,480,000
Percentage of Srini Akkaraju and Michael Dybbs’ 13F Portfolio: 7.95%
Number of Hedge Fund Holders: 14

Nkarta, Inc. (NASDAQ:NKTX) develops and sells cell therapies for cancer treatment. The company was incorporated in 2015 and is ranked second on the list of 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Nkarta, Inc. (NASDAQ:NKTX) currently has a market capitalization of $896.37 million. 

On August 12, Nkarta, Inc. (NASDAQ:NKTX) posted earnings for the second quarter of 2021. It declared earnings per share of -$0.66, missing the analysts’ expectations by $0.02. On July 15, Oppenheimer analyst Matthew Biegler initiated coverage of Nkarta, Inc. (NASDAQ:NKTX) with an “Outperform” rating and gave a price target of $75. 

Srini Akkaraju and Michael Dybbs’ Samsara BioCapital owns $64.48 million stake in Nkarta, Inc. (NASDAQ:NKTX). RA Capital Management is Nkarta, Inc.’s (NASDAQ:NKTX) most significant stakeholder, with 5.61 million shares worth $177.63 million.